March 19 (Reuters) - Paratek Pharmaceuticals:
* PARATEK PHARMACEUTICALS TO ACQUIRE OPTINOSE, CREATING
SIGNIFICANT COMMERCIAL EXPANSION OPPORTUNITIES FOR XHANCE® IN
CHRONIC RHINOSINUSITIS (CRS)
* PARATEK PHARMACEUTICALS - TOTAL TRANSACTION VALUE OF UP TO
$330
MILLION
* PARATEK PHARMACEUTICALS- POTENTIAL CONSIDERATION OF UP TO
$14
PER SHARE, INCLUDING UPFRONT CONSIDERATION OF $9 PER SHARE
Source text:
Further company coverage: